Table 2.
FSFI and hormone levels.
| Total cohort | |||||
|---|---|---|---|---|---|
| Variables | RRSO baseline | RRSO 1 year | P 1 | Controls | P 2 |
| n = 39 | n = 39 | n = 67 | |||
| FSFI total score (2-36) | 26.6 (15.6-29.1) | 23.0 (4.2-28.1) | .062 | 30.2 (26.6-32.5) | <.001 |
| Desire (1.2-6) | 2.4 (1.2-3.6) | 2.4 (1.2-3.0) | .123 | 3.0 (3.0-4.2) | <.001 |
| Arousal (0-6) | 3.9 (1.7-5.0) | 3.6 (0.6-4.7) | .074 | 5.1 (3.9-5.7) | <.001 |
| Lubrication (0-6) | 4.5 (2.0-5.6) | 3.6 (0.0-5.7) | .196 | 5.7 (4.8-6.0) | <.001 |
| Orgasm (0-6) | 4.8 (2.0-5.6) | 3.6 (0.0-5.2) | .023 | 5.6 (4.4-6.0) | <.001 |
| Satisfaction (0.8-6) | 3.6 (2.4-5.2) | 3.6 (2.4-5.2) | .813 | 5.2 (4.6-5.6) | <.001 |
| Pain (0-6) | 5.4 (0.0-6.0) | 3.2 (0.0-6.0) | .032 | 6.0 (5.6-6.0) | <.001 |
| Proportion with sexual dysfunction FSFI total score < 26.55 (%) | 17 (43.6) | 26 (66.7) | .070a | 17 (25.4) | <.001b |
| n = 35 | n = 35 | n = 58 | |||
| Total testosterone (nmol L−1) | 0.5 (0.4-0.8) | 0.5 (0.4-0.7) | .522 | 0.6 (0.4-0.8) | .36 |
| SHBG (nmol L−1) | 74 (51-94) | 77 (51-113) | .212 | 66 (46-89) | .176 |
| FAI (nmol L−1) | 0.7 (0.4-1.1) | 0.6 (0.5-1) | .588 | 0.9 (0.6-1.3) | .041 |
All values are presented as median (IQR) except FSD (female sexual dysfunction) presented in n (%).
FSFI, Female Sexual Function Index; FAI, free androgen index; RRSO, risk-reducing salpingo-oophorectomy; SHBG, sexual hormone-binding globulin.
P 1: Wilcoxon’s signed-rank test for comparison between baseline and 1-year follow-up.
P 2: Wilcoxon rank-sum test for group difference (RRSO group 1 year vs. controls).
aMcNemar's Chi-squared test with continuity correction.
bFisher’s exact test for group difference (RRSO group 1 year vs. controls).